Authorization is based on the results from three Phase 3 multicenter, randomized, double-blind, placebo-controlled registrational clinical trials evaluating the efficacy and safety or RINVOQ in monotherapy or in combination with topical corticosteroids. 1 RINVOQ demonstrated improvements in skin clearance and itch reduction compared to placebo. Milestone marks the third Health Canada-approved indication for RINVOQ .